NEOS S&P 500 High Income ETF (SPYI) Stock Price Today
Aura AI Summary
Key Stats
- $12.36BMarket Cap
- 2,393,294Volume
- Income / Options OverlaySector
- $54.4252W High
- $47.9852W Low
- 55 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track NEOS S&P 500 High Income ETF (SPYI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, NEOS S&P 500 High Income ETF has traded between a low of $47.98 and a high of $54.42, highlighting its annual price range. Buy and sell NEOS S&P 500 High Income ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Most Recent News
First Hydrogen completes unmanned ground vehicle, gains exclusive global patent rights.
First Hydrogen Corp. has successfully built its unmanned ground vehicle (UGV), achieving a key development milestone and securing exclusive worldwide rights to the related patented technology for the patent's remaining life, with a 1% royalty on sale...

Coiled Therapeutics expects first safety data for new AO-252 cancer drug formulation by end of 2026
Coiled Therapeutics plans to report initial safety and pharmacokinetic data for its new AO-252 cancer drug formulation by the end of 2026 after dosing up to 30 patients. The new lipid-based softgel aims to improve drug absorption and consistency, wit...

Poolbeg Pharma doses 8 patients in trial to prevent cancer immunotherapy side effect CRS
Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 to prevent cytokine release syndrome (CRS), a dangerous immune reaction caused by cancer immunotherapy. The trial targets multiple myeloma patients receiving teclistamab, a...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.